MSB Trading - 2020, page-18853

My thoughts on how this 30% of patients with 30 days treatment is to be played out...

It should go something like this:

1. Mesoblast to announced that they reached this target and has sent it to DMC
2. DMC to review data and determine next step - I'm assuming they call the trial to stop due to overwhelming success
3. FDA to approve Rem-L for Covid-19 ARDS treatment

With #1:

• Does this actually have to occur?
• Has it occured? If not, then when will this occur - any days now!
• Does NIH have to inform Mesoblast?
• Does Mesoblast have to inform the market?
• Where is the canary in the coal mine - e.g. change of status on the government trial website i.e. "Active - but not recruiting"

With #2:

• How long does this take?
• How and who do they inform that the trial must stop?
• When will Mesoblast inform the market?
• If the trial was to continue, will the market also be informed?

With #3:

• How long does this take?
• What are the steps involved here? Another long drawn out BLA submission?
• Surely, the most logical & expedient action is for the FDA to approve Ryoncil first and then extend the label to Covid-19
• How will this feed into the WH Covid-19 Warp Speed initiative?

With all the above, when will a partnership be announced?
With whom? $$$? Terms?

Anyway, a fair bit to play out
A lot is at stake, but both safety and expedient are at the forefront of all discussions

GLTASHs
Onwards and upwards
Stay strong, go long - HODL

BTW - please don't feed the trolls